ESLAW
Estrella Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.08
+3.33%Price chart
Jun 9Jun 18Jul 2Jul 8Jul 22Aug 4Aug 11Aug 25
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$2.87M
MomentumView details →
1D Return
+3.33%
YTD Return
+55.00%
RSI (14)
46.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$2.87M
RSI (14)
46.2
MomentumView details →
1D Return
+3.33%
YTD Return
+55.00%
Similar companies
Latest newsMore news →
Estrella Immunopharma activated University Hospitals Cleveland Medical Center as the fourth clinical site for its Phase I/II STARLIGHT-1 trial of EB103 in B-cell non-Hodgkin's lymphoma.25d agoEstrella Immunopharma activated Oregon Health & Science University as the third clinical site for its Phase I/II STARLIGHT-1 trial of EB103 in B-cell non-Hodgkin's lymphoma.33d agoEstrella Immunopharma dosed the first patient in the dose-expansion phase of its STARLIGHT-1 clinical trial for EB103 therapy in advanced B-cell non-Hodgkin's lymphoma.43d ago